While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

A patient advocacy group has started a campaign to stop Novo Nordisk from following through on a plan to stop making insulin product Levemir, arguing that it could leave some diabetics without an ...

Recent price cuts by major insulin manufacturers may appear to address affordability challenges, but they primarily target older insulin drugs nearing patent expiration. This tactic, coupled with the ...

Novo Nordisk stock gains as it reports better-than-expected fourth-quarter 2024 results driven by strong sales of Diabetes ...

FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.

Meanwhile Novo Nordisk has also seen its ranking surge ... strong performances from GLP-1 analogue Victoza, insulin analogue Levemir and the 2015 launch of longer-acting insulin analogue Tresiba.

Levemir (insulin detemir) is safe to receive while pregnant or breastfeeding. However, factors such as the form you get or the condition the drug helps treat may determine whether you should ...

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...